OncoCell MDx Names McDonough as New President and Chief Executive Officer
2 May 2019 - - US-based diagnostics developer OncoCell MDx has appointed Mark McDonough as its president, chief executive officer and member of the board of directors, the company said.

McDonough succeeds company co-founder, investor and chairman/CEO Harry Stylli, Ph.D. Stylli continues as the executive chairman of the company.

McDonough most recently served as the chief business officer at Phosphorus, a genomic health company, where he helped increase the company's revenue by more than tenfold in less than a year.

Prior to joining Phosphorus, McDonough served as chief executive officer and president of CombiMatrix, a publicly held molecular diagnostics company performing DNA-based testing services for reproductive health and developmental disorders, through its acquisition by Invitae Corp.

He also held executive and management positions with US LABS (acquired by LabCorp) and Ventana Medical Systems (acquired by Roche) as well as Pathwork Diagnostics.

McDonough is currently an advisor for Phosphorus and Natal Health. He is a former navigator in the US Navy and holds a B.S. in Finance from Miami University.

OncoCell MDx is a privately held company developing and commercializing novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School.

The company's noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications.